Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 2/20 | 0.56 |
| ▸ | NAMPT | P43490 | 5/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 3/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6742058 | 0.83 | NAMPT (0.56) | CCR2NAMPTGRIN2BFAAHEPHX2 | |
| SCHEMBL6738695 | 0.81 | NAMPT (0.46) | CCR2NAMPTGRIN2BFAAHEPHX2 | |
| SCHEMBL6743525 | 0.81 | CCR2 (0.44) | CCR2NAMPTGRIN2BFAAHEPHX2 | |
| SCHEMBL6739530 | 0.79 | NAMPT (0.54) | CCR2NAMPTGRIN2BFAAHEPHX2 | |
| SCHEMBL6733580 | 0.78 | GRIN2B (0.46) | CCR2NAMPTGRIN2BFAAH | |
| SCHEMBL6737659 | 0.78 | EPHX2 (0.48) | CCR2NAMPTGRIN2BFAAHEPHX2 | |
| SCHEMBL6739974 | 0.78 | KCNH2 (0.49) | CCR2NAMPTGRIN2BFAAHMAPT | |
| SCHEMBL6733184 | 0.76 | GPR119 (0.49) | NAMPTGRIN2BEPHX2MAPTPANK3 | |
| SCHEMBL6986280 | 0.75 | HRH3 (0.43) | CCR2SIGMAR1HRH3 | |
| SCHEMBL6733799 | 0.75 | FAAH (0.47) | NAMPTGRIN2BFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040229900-A1 | Bispidine compounds useful in the treatment of cardiac arrythmias | ASTRAZENECA AB (SE) | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229900-A1 | Bispidine compounds useful in the treatment of cardiac arrythmias | ADRA1B, ADRB2, ADRA1D | CCR2 3484/4885NAMPT 4702/4885GRIN2B 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.